Baricitinib

Baricitinib

Clinical data
Trade names	Olumiant
Routes of administration	By mouth (tablets)
ATC code	L04AA37 (WHO)
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Synonyms	INCB28050, LY3009104
CAS Number	1187594-09-7
PubChem CID	44205240
ChemSpider	26373084
UNII	ISP4442I3Y
KEGG	D10308
ChEMBL	CHEMBL2105759
PDB ligand	3JW (PDBe, RCSB PDB)
ECHA InfoCard	100.219.080
Chemical and physical data
Formula	C16H17N7O2S
Molar mass	371.42 g/mol
3D model (Jmol)	Interactive image
SMILES CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) Key:XUZMWHLSFXCVMG-UHFFFAOYSA-N

Baricitinib (trade name Olumiant) is an investigational drug for rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.

In January 2016, Eli Lilly submitted a new drug application to the US FDA for the approval of baricitinib to treat moderately-to-severely active RA.

In December 2016, the European Committee for Medicinal Products for Human Use (CHMP) recommended the approval of baricitinib as a second-line therapy for RA in adults, either alone or in combination with methotrexate.

Despite widespread expectations that the FDA would approve baricitinib for RA, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety.

Other JAK inhibitors include tofacitinib, currently approved for the treatment of RA, and ruxolitinib.